Myeloma UK intensifies its initiatives as part of an ambitious program to make Myeloma history. This new collaborative model will combine the patient insight from Myeloma UK with the experience and expertise of the UK Myeloma UK Research Alliance and the University of Leeds Clinical Trials Research Unit (CTRU) to develop a portfolio of early phase clinical trials. The investment from Myeloma UK will help catalyze trial development and facilitate funding from external sources such as pharmaceutical companies and diagnostic companies to support the delivery of innovative trials developed through the UKMRA-Myeloma UK-CARP. Follow the link to Pharmiweb for more details.

Source: PharmiWeb.com

Pin It on Pinterest